To specifically target the dissemination of BC cells from primary tumours, according to clinical findings showing that loss of WNT5a predicts faster BC spread, a decade ago, Safholm A and colleagues tested their novel WNT5a mimicking hexapeptide, Foxy-5, (ClinicalTrials.gov Identifier: NCT02655952), in preclinical and clinical models as a novel therapeutic strategy to inhibit BC metastasis [77]. Here, WNT5A is linked to breast cancer.